Združene države Amerike - angleščina - NLM (National Library of Medicine)

physicians total care, inc. - colesevelam hydrochloride (unii: p4sg24wi5q) (colesevelam - unii:1xu104g55n) - colesevelam hydrochloride 625 mg - welchol is indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (ldl-c) in adults with primary hyperlipidemia (fredrickson type iia) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme a (hmg coa) reductase inhibitor (statin). welchol is indicated as monotherapy or in combination with a statin to reduce ldl-c levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. ldl-c remains ≥ 190 mg/dl or b. ldl-c remains ≥ 160 mg/dl and - there is a positive family history of premature cardiovascular disease or - two or more other cvd risk factors are present in the pediatric patient. lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate [see clinical studies (14.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

zydus lifesciences limited - colesevelam hydrochloride (unii: p4sg24wi5q) (colesevelam - unii:1xu104g55n) - colesevelam hydrochloride tablets are indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (ldl-c) in adults with primary hyperlipidemia. colesevelam hydrochloride tablets are indicated to reduce ldl-c levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (hefh) who are unable to reach ldl-c target levels despite an adequate trial of dietary therapy and lifestyle modification. - colesevelam hydrochloride should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis. - the effect of colesevelam hydrochloride on cardiovascular morbidity and mortality has not been determined. - colesevelam hydrochloride has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase 4 inhibitor. - colesevelam hydrochloride has not been studied in fredrickson type i, iii, iv, and v dyslipidemias. - colesevelam hydrochloride has not bee

Združene države Amerike - angleščina - NLM (National Library of Medicine)

avera mckennan hospital - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - colestipol hydrochloride 1 g

Izrael - angleščina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - colestipol hydrochloride - granules - colestipol hydrochloride 5 g/sachet - adjunctive therapy to diet in the managnent of elevated cholesterol levels.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considered in patients with severe elevations of ldl-c or with definite chd. according to the ncep guidelines, the goal of treatment is to lower ldl-c and ldl-c is to be used to initiate and assess treatment response. only if ldl-c levels are not available, should the total-c be used to monitor therapy. the ncep treatment guidelines are shown below. * coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** other risk factors for coronary heart disease (chd) include: age (males: ≥ 45 years; female: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature chd; current cigarette smoking; hypertension; confirmed hdl-c < 35 mg/dl (0.91 mmol/l); and diabetes mellitus. subtract one risk factor if hdl-c is ≥ 60 mg/dl (1.6 mmol/l). colestipol hydrochloride tablets are contraindicated in those individuals who have shown hypersensitivity to any of their components.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

remedyrepack inc. - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considere

Združene države Amerike - angleščina - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considere

Združene države Amerike - angleščina - NLM (National Library of Medicine)

american health packaging - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considered in patients with severe elevations of ldl-c or with definite chd. according to the ncep guidelines, the goal of treatment is to lower ldl-c, and ldl-c is to be used to initiate and assess treatment response. only if ldl-c levels are not available, should the total-c be used to monitor therapy. the ncep treatment guidelines are shown below. ldl-cholesterol mg/dl (mmol/l) definite atheroschlerotic disease * two or more other risk factors † initiation level goal no no ≥ 190 (≥ 4.9) < 160 (< 4.1) no yes ≥ 160 (≥ 4.1) < 130 (< 3.4) yes yes or no ≥ 130 (≥ 3.4) ≤ 100 (≤ 2.6) colestipol hydrochloride tablets are contraindicated in those individuals who have shown hypersensitivity to any of its components.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considere

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bora pharmaceuticals laboratories inc. - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considered in patients with severe elevations of ldl-c or with definite chd. according to the ncep guidelines, the goal of treatment is to lower ldl-c, and ldl-c is to be used to initiate and assess treatment response. only if ldl-c levels are not available, should the total-c be used to monitor therapy. the ncep treatment guidelines are shown below. ldl-cholesterol mg/dl (mmol/l) definite atherosclerotic disease * two or more other risk factor † initiation level goal no no ≥190 <160 (≥4.9) (<4.1) no yes ≥160 <130 (≥4.1) (<3.4) yes yes or no ≥130 ≤100 (≥3.4) (≤2.6) * coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). † other risk factors for coronary heart disease (chd) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature chd; current cigarette smoking; hypertension; confirmed hdl-c <35 mg/dl (0.91 mmol/l); and diabetes mellitus. subtract one risk factor if hdl-c is ≥60 mg/dl (1.6 mmol/l). colestipol hydrochloride tablets are contraindicated in those individuals who have shown hypersensitivity to any of their components.